Publications
Detailed Information
Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele Frequency
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choe, Pyoeng Gyun | - |
dc.contributor.author | Park, Wan Beom | - |
dc.contributor.author | Song, Jin Su | - |
dc.contributor.author | Kim, Nak-Hyun | - |
dc.contributor.author | Song, Kyoung-Ho | - |
dc.contributor.author | Park, Sang Won | - |
dc.contributor.author | Kim, Hong Bin | - |
dc.contributor.author | Kim, Nam Joong | - |
dc.contributor.author | Oh, Myoung-don | - |
dc.date.accessioned | 2024-04-26T01:12:01Z | - |
dc.date.available | 2024-04-26T01:12:01Z | - |
dc.date.created | 2021-12-10 | - |
dc.date.issued | 2010-10 | - |
dc.identifier.citation | Journal of Korean Medical Science, Vol.25 No.10, pp.1427-1430 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://hdl.handle.net/10371/199749 | - |
dc.description.abstract | Hyperbilirubinemia is frequently observed in Caucasian HIV patients treated with atazanavir. UDP-glucuronosyltransferase 1A1 polymorphism, UGT1A1*28, which is associated with atazanavir-induced hyperbilirubinemia, is less common in Asians than in Caucasians. However, little is known about the incidence of atazanavir-associated hyperbilirubinemia in Asian populations. Our objective was to investigate the incidence of and tolerability of atazanavir-associated hyperbilirubinemia in Korean HIV patients. The prevalence and cumulative incidence of atazanavir-associated hyperbilirubinemia and UGT1A1*28 allele frequency was investigated in 190 Korean HIV-infected patients treated with atazanavir 400 mg per day. The UGT1A1*28 were examined by direct sequencing of DNA from peripheral whole blood. The UGT1A1*28 allele frequency was 11%. The cumulative incidence of any grade of hyperbilirubinemia was 77%, 89%, 98%, and 100%, at 3, 12, 24, and 30 months, respectively. The cumulative incidence of severe (grade 3-4) hyperbilirubinemia was 21%, 41%, 66%, and 75%, at 3, 12, 24, and 30 months, respectively. However, the point prevalence of severe hyperbilirubinemia did not increase with time and remained around 25%. Our data suggest that atazanavir-associated hyperbilirubinemia is common but transient in a population with low UGT1A1*28 allele frequency. | - |
dc.language | 영어 | - |
dc.publisher | 대한의학회 | - |
dc.title | Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele Frequency | - |
dc.type | Article | - |
dc.identifier.doi | 10.3346/jkms.2010.25.10.1427 | - |
dc.citation.journaltitle | Journal of Korean Medical Science | - |
dc.identifier.wosid | 000282232800004 | - |
dc.identifier.scopusid | 2-s2.0-78449293357 | - |
dc.citation.endpage | 1430 | - |
dc.citation.number | 10 | - |
dc.citation.startpage | 1427 | - |
dc.citation.volume | 25 | - |
dc.identifier.kciid | ART001483583 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Park, Wan Beom | - |
dc.contributor.affiliatedAuthor | Park, Sang Won | - |
dc.contributor.affiliatedAuthor | Kim, Hong Bin | - |
dc.contributor.affiliatedAuthor | Kim, Nam Joong | - |
dc.contributor.affiliatedAuthor | Oh, Myoung-don | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GENETIC POLYMORPHISMS | - |
dc.subject.keywordPlus | LOPINAVIR/RITONAVIR | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | HIV | - |
dc.subject.keywordAuthor | Acquired Immunodeficiency Syndrome | - |
dc.subject.keywordAuthor | Atazanavir | - |
dc.subject.keywordAuthor | Hyperbilirubinemia | - |
dc.subject.keywordAuthor | Jaundice | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.